03.06.2024 - Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of Nova Scotia living with either type 1 or type 2 diabetes who use intensive insulin and meet .
Dexcom ONE+ is available today in Spain, Belgium, and Poland with the Netherlands launching next week, and additional countries to be announced in the coming months.
New system continues to.
Leading payer and health system stakeholders reviewed literature and shared insights on the value of real-time continuous glucose monitoring (rtCGM) in type 2 diabetes (T2D) population health.
Analysis of claims data showed reduced utilization and costs among patients with nonintensively treated type 2 diabetes (T2D) using self-monitoring of blood glucose compared with continuous glucose monitoring.